Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
Charged with protecting the innovation arising from MedImmune, the global biologics research and development arm of AstraZeneca, as well as AstraZeneca’s innovative medicines and early development biotech units, Scott Alban’s job is far from insignificant.
Alban was behind AstraZeneca and MedImmune’s recent transformation of its global IP organisation to circumvent geographic and cultural barriers between the IP professionals who support pharmaceuticals and biologics across seven global sites.
“We wanted to empower our attorneys and other patent professionals to work collaboratively across multiple therapy areas, technology platforms and therapeutic modalities,” he says.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Scott Alban, LSIPR 50 2018, AstraZeneca, MedImmune, biology, research and development, innovation, biotech